Back to Search Start Over

MPT0E028, a novel pan-HDAC inhibitor, prevents pulmonary fibrosis through inhibition of TGF-β-induced CTGF expression in human lung fibroblasts: Involvement of MKP-1 activation.

Authors :
Liu, Chia-Hao
Lee, Hong-Sheng
Liou, Jing-Ping
Hua, Hung-Sheng
Cheng, Wun-Hao
Yuliani, Fara Silvia
Chen, Bing-Chang
Lin, Chien-Huang
Source :
European Journal of Pharmacology. Aug2024, Vol. 977, pN.PAG-N.PAG. 1p.
Publication Year :
2024

Abstract

Histone deacetylase (HDAC) inhibitors are potential candidates for treating pulmonary fibrosis. MPT0E028, a novel pan-HDAC inhibitor, has been reported to exhibit antitumor activity in several cancer cell lines. In this study, we investigated the mechanism underlying the inhibitory effects of MPT0E028 on the expression of fibrogenic proteins in human lung fibroblasts (WI-38). Our results revealed that MPT0E028 inhibited transforming growth factor-β (TGF-β)-, thrombin-, and endothelin 1-induced connective tissue growth factor (CTGF) expression in a concentration-dependent manner. In addition, MPT0E028 suppressed TGF-β-stimulated expression of fibronectin, collagen I, and α-smooth muscle actin (α-SMA). Furthermore, MPT0E028 inhibited the TGF-β-induced phosphorylation of c-Jun N-terminal kinase (JNK), p38, and extracellular signal-regulated kinase (ERK). MPT0E028 reduced the increase in SMAD3 and c-Jun phosphorylation, and SMAD3-and activator protein-1 (AP-1)-luciferase activities under TGF-β stimulation. Transfection with mitogen-activated protein kinase phosphatase-1 (MKP-1) siRNA reversed the suppressive effects of MPT0E028 on TGF-β-induced increases in CTGF expression; JNK, p38, and ERK phosphorylation; and SMAD3 and AP-1 activation. Moreover, MPT0E028 increased MKP-1 acetylation and activity in WI-38 cells. Pretreatment with MPT0E028 reduced the fibrosis score and fibronectin, collagen, and α-SMA expression in bleomycin-induced pulmonary fibrosis mice. In conclusion, MPT0E028 induced MKP-1 acetylation and activation, which in turn inhibited TGF-β-stimulated JNK, p38, and ERK phosphorylation; SMAD3 and AP-1 activation; and subsequent CTGF expression in human lung fibroblasts. Thus, MPT0E028 may be a potential drug for treating pulmonary fibrosis. • MPT0E028, a novel pan-HDAC inhibitor, inhibits TGF-β-, thrombin-, and ET-1-induced CTGF expression in human lung fibroblasts. • MKP-1 participates in MPT0E028-suppressed CTGF expression caused by TGF-β in human lung fibroblasts. • MPT0E028 attenuates bleomycin-induced pulmonary fibrosis and ECM deposition. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
00142999
Volume :
977
Database :
Academic Search Index
Journal :
European Journal of Pharmacology
Publication Type :
Academic Journal
Accession number :
178149445
Full Text :
https://doi.org/10.1016/j.ejphar.2024.176711